Odapipam is a selective dopamine D1 receptor agonist that has been primarily investigated for its potential in treating psychiatric and neurological disorders, including Parkinson's disease and cognitive impairments. It has shown promise in research settings for managing conditions like schizophrenia, particularly addressing negative and cognitive symptoms through enhancement of dopamine D1 signaling pathways. Due to its selectivity for D1 receptors, it offers a targeted approach that may improve cognition and motor function with a potentially lower risk of extrapyramidal side effects compared to traditional antipsychotics that block D2 receptors. It has also been explored for use in substance abuse and addiction disorders, where D1 receptor activation can modulate reward and drug-seeking behaviors. Additionally, odapipam serves as a valuable pharmacological tool in neuroscience research to elucidate the roles of D1 receptors in cognitive processes, mood regulation, and motor control. Its applications remain largely experimental, with ongoing clinical development.